91170-96-6

Basic information

• Product Name: 1,2-dimethoxy-4-(3-methylphenylsulphonyl)-5-methylbenzene
• CAS NO: 91170-96-6
• Molecular Weight: 306.383
• Mol File: 91170-96-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,2-dimethoxy-4-(3-methylphenylsulphonyl)-5-methylbenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-dimethoxy-4-(3-methylphenylsulphonyl)-5-methylbenzene(91170-96-6)
• EPA Substance Registry System: 1,2-dimethoxy-4-(3-methylphenylsulphonyl)-5-methylbenzene(91170-96-6)

Safety Data

• Hazardous Substances Data: 91170-96-6(Hazardous Substances Data)

Upstream product

• 494-99-5 1,2-dimethoxy-4-methylbenzene 
• 617-97-0 m-toluenesulfonic acid 

Relevant articles and documents

Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions

The invention relates to novel benzodioxole derivatives of the general formula I STR1 in which R1 represents an unsubstituted or substituted, aliphatic, aromatic or heteroaromatic radical, alk represents an alkylene, alkenylene or alkylidene radical having a maximum of 5 carbon atoms, n1 represents 0, 1 or 2 n2 represents 0 or 1, R2, R3 and R4 each represents, independently of the others, hydrogen, lower alkyl, lower alkoxy or halogen, and A represents the radical --O--R5, wherein R5 represents hydrogen or an unsubstituted or substituted, aliphatic or araliphatic hydrocarbon radical, or A represents the radical STR2 in which either R6 and R7 each represents, independently of the other, hydrogen or lower alkyl, or R6 and R7 are bonded to one another and, together with the adjacent nitrogen atom, represent optionally lower alkyl-substituted tetra- to hexa-methyleneimino, 4-morpholinyl or 1H-tetrazol-1-yl, such as, for example, 5-methyl-6-phenylsulphonyl-1,3-benzodioxole-2-carboxylic acid. The invention relates also to salts of compounds of the general formula I in which A represents OR5 wherein R5 represents hydrogen, with bases, and to acid addition salts of compounds of the general formula I in which the radical R1 has a basic character and to processes for the manufacture of the above compounds and the salts thereof and to pharmaceutical compositions containing them. These novel substances have diuretic and supplementary uricosuric action and may be used, preferably in the form of appropriate pharmaceutical compositions, for the treatment of oedema and hypertension.